Overview
flowchart TD
therapeutics["therapeutics"] -->|"protects against"| age_related_cognitive_decline["age-related cognitive decline"]
therapeutics["therapeutics"] -->|"inhibits"| neuroinflammation["neuroinflammation"]
Therapeutics["Therapeutics"] -->|"references"| SIRT6["SIRT6"]
Therapeutics["Therapeutics"] -->|"references"| AADC["AADC"]
Therapeutics["Therapeutics"] -->|"references"| CX3CR1["CX3CR1"]
Therapeutics["Therapeutics"] -->|"references"| BACE1["BACE1"]
Therapeutics["Therapeutics"] -->|"references"| APOE["APOE"]
Therapeutics["Therapeutics"] -->|"references"| VCP["VCP"]
Therapeutics["Therapeutics"] -->|"references"| GFAP["GFAP"]
Therapeutics["Therapeutics"] -->|"references"| NURR1["NURR1"]
Therapeutics["Therapeutics"] -->|"references"| BDNF["BDNF"]
Therapeutics["Therapeutics"] -->|"references"| NLRP3["NLRP3"]
Therapeutics["Therapeutics"] -->|"references"| TFEB["TFEB"]
Therapeutics["Therapeutics"] -->|"references"| PPARGC1A["PPARGC1A"]
style therapeutics fill:#4fc3f7,stroke:#333,color:#000
NeuroMito Therapeutics is a biotechnology company focused on developing next-generation mitochondrial antioxidants for the treatment of Parkinson's disease and related neurodegenerative disorders. Founded in 2018 and headquartered in Boston, Massachusetts, NeuroMito's proprietary mitochondrial-targeted antioxidant platform addresses the oxidative stress component of PD pathogenesis["@neuromito"].
...Overview
Mermaid diagram (expand to render)
NeuroMito Therapeutics is a biotechnology company focused on developing next-generation mitochondrial antioxidants for the treatment of Parkinson's disease and related neurodegenerative disorders. Founded in 2018 and headquartered in Boston, Massachusetts, NeuroMito's proprietary mitochondrial-targeted antioxidant platform addresses the oxidative stress component of PD pathogenesis["@neuromito"].
The company's lead program, NMT-101, is a mitochondria-targeted nitroxide compound designed to selectively scavenge reactive oxygen species (ROS) within mitochondria while preserving essential cellular signaling functions.
Scientific Rationale
Oxidative Stress in Parkinson's Disease
Oxidative stress is a central pathological feature in Parkinson's disease:
- Elevated ROS production: Damaged mitochondria produce excess superoxide
- Reduced antioxidant capacity: Glutathione levels are depleted in PD substantia nigra
- Iron accumulation: Ferritin-bound iron catalyzes Fenton reactions
- Lipid peroxidation: Increased 4-HNE and MDA in PD brains
- DNA damage: Elevated 8-OHdG in mitochondrial DNA
Limitations of Current Antioxidants
Previous antioxidant approaches have shown limited efficacy in PD clinical trials:
- Vitamin E: Neutralized trial showed no benefit[@datatop]
- CoQ10: Phase 3 showed marginal effects at high doses
- Traditional antioxidants: Poor mitochondrial targeting, limited CNS penetration
NMT-101 Mechanism
NMT-101 overcomes these limitations through:
Mitochondrial targeting: TPP (triphenylphosphonium) moiety drives accumulation in mitochondria
Catalytic ROS scavenging: Nitroxide radical cycles between oxidized and reduced forms
Membrane permeability: Designed for CNS penetration
Signal preservation: Does not block beneficial ROS signalingPipeline Overview
| Drug | Mechanism | Indication | Phase | Status |
|------|-----------|------------|-------|--------|
| NMT-101 | Mitochondrial antioxidant | Parkinson's Disease | Phase 2 | Active |
| NMT-201 | ROS modulator | PD with dementia | Phase 1 | IND-cleared |
| NMT-301 | Mitocholuorophyll | ALS | Discovery | Research |
Clinical Development
NMT-101 Phase 2 Trial
NMT-101-CL-002 (2024-2025): A 52-week, randomized, double-blind, placebo-controlled Phase 2 trial in patients with early-to-moderate Parkinson's disease[@nmt]:
| Parameter | Value |
|-----------|-------|
| Patients | 180 (60 per arm) |
| Doses | 10mg, 30mg, placebo |
| Duration | 52 weeks |
| Primary endpoint | Change in MDS-UPDRS total score |
| Secondary endpoints | Motor complications, non-motor symptoms, biomarker changes |
Enrollment criteria:
- Age 40-80 years
- Hoehn & Yahr stages 1-3
- Disease duration 1-10 years
- Stable dopaminergic therapy
Biomarker Program
NMT-101 development includes robust biomarker assessment:
- Mitochondrial function: ATP, lactate, PINK1 levels
- Oxidative stress: 8-OHdG, 4-HNE in CSF
- Neurodegeneration: Neurofilament light chain (NfL)
- Neuroinflammation: IL-6, TNF-α in CSF
Preclinical Data
MPTP Model
In the MPTP mouse model of PD, NMT-101:
- Protected tyrosine hydroxylase-positive neurons in substantia nigra
- Preserved striatal dopamine content
- Improved performance on rotarod and cylinder tests
- Reduced activated microglia in the striatum
Rotenone Model
In chronic rotenone-exposed rats:
- Maintained Complex I activity
- Reduced mitochondrial ROS generation
- Improved gait parameters
- Protected against dopamine neuron loss
Aged Animals
In 18-month-old mice:
- Restored age-related mitochondrial function decline
- Improved spatial memory (Morris water maze)
- Reduced oxidative damage markers
- Enhanced locomotor activity
| Attribute | Details |
|-----------|---------|
| Headquarters | Boston, Massachusetts, USA |
| Founded | 2018 |
| CEO | Dr. Robert W. Harrison |
| CSO | Dr. Linda K. Park |
| Funding | Series A ($18M, 2019), Series B ($40M, 2022), Series C ($65M, 2025) |
| Investors | Atlas Venture, Novartis Venture Fund, Bristol Myers Squibb |
Scientific Advisory Board
- Dr. Timothy J. K. Collier — Mitochondrial medicine, Massachusetts General Hospital
- Prof. Marie-Françoise G. Chesselet — Neurobiology, UCLA
- Dr. Michael T. M. Green — Pharmacology, Johns Hopkins University
Competitive Landscape
| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| NeuroMito | NMT-101 | Mitochondrial antioxidant | Phase 2 |
| Clene | CNM-Au8 | Catalytic antioxidant | Phase 2 |
| Vandria | VNA-100 | Mitochondrial modulator | Preclinical |
| Napa | NP-101 | Mitochondria protectant | Phase 1 |
Cross-References
- [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons)
- [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Substantia Nigra](/cell-types/dopaminergic-neurons)
- [Neuroprotection](/mechanisms/neuroprotection-pathway)
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Oxidative Stress](/mechanisms/oxidative-stress)
- [Mitochondrial Antioxidants](/therapeutics/mitochondrial-antioxidants-neurodegeneration)
- [Neuroprotection](/treatments/neuroprotection)
- [Clinical Trials](/clinical-trials)
References
Unknown, NeuroMito Therapeutics Corporate Website (n.d.)
[Unknown, DATATOP Study - NEJM (n.d.)](https://doi.org/10.1056/NEJM1994-0331-1503)
Unknown, NMT-101 Phase 2 Clinical Trial (n.d.)
[Unknown, Mitochondrial-Targeted Antioxidants - Pharmacological Reviews (n.d.)](https://doi.org/10.1124/pharmrev.123.000972)